Sep 13th 2012 - Edison Investment Research today published a report on Biotie Therapies Corp entitled "Funded Ahead Of Catalysts". In summary, the report says:
Biotie’s €30m financing helps to bridge a funding gap to reaching some potentially transformational milestones and consolidates its strategic relationship with Lundbeck. Biotie’s cash runway should now extend into 2014. As well as seeking licensing deals on three Phase II-ready assets, Biotie is facing two key catalysts due by the end of 2012 – European approval decision on alcohol dependence drug Selincro (triggering an undisclosed milestone from Lundbeck) and Phase IIb results for Parkinson’s disease candidate tozadenant (if positive, UCB to assume development).
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »